FRHC:NASDAQFreedom Holding Corp. Analysis
Data as of 2026-04-04 - not real-time
$151.64
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Freedom Holding Corp. (FRHC) is trading at $151.64, well below its DCF‑derived fair value of $488, suggesting a sizable upside potential. The stock sits just beneath the 20‑day SMA ($139.34) and above the 50‑day SMA ($128.75), while the 200‑day SMA ($147.42) is also supportive, indicating a neutral‑to‑bullish bias. However, the RSI is extremely high at 74.7, flagging an overbought condition, and the MACD histogram remains modest (+0.71) despite a bullish signal, hinting at limited short‑term momentum.
Fundamentally, FRHC reports a meager profit margin of 0.18% and a trailing P/E of 7,582, reflecting near‑zero earnings, yet forward earnings of $4.50 imply a more reasonable forward P/E of ~34. The company holds abundant cash ($3.05 B) but also carries substantial debt ($2.17 B) leading to a high debt‑to‑equity ratio. Recent news highlights rapid fintech expansion, $1.69 B revenue and $144.5 M net income in the first nine months of FY2026, and confirmation of stable credit ratings by S&P, underscoring improving profitability and credit quality. These mixed signals point to a stock that is technically overbought but fundamentally undervalued relative to its intrinsic estimate, with medium‑to‑high risk stemming from volatility (31% 30‑day) and sector‑specific regulatory exposure.
Fundamentally, FRHC reports a meager profit margin of 0.18% and a trailing P/E of 7,582, reflecting near‑zero earnings, yet forward earnings of $4.50 imply a more reasonable forward P/E of ~34. The company holds abundant cash ($3.05 B) but also carries substantial debt ($2.17 B) leading to a high debt‑to‑equity ratio. Recent news highlights rapid fintech expansion, $1.69 B revenue and $144.5 M net income in the first nine months of FY2026, and confirmation of stable credit ratings by S&P, underscoring improving profitability and credit quality. These mixed signals point to a stock that is technically overbought but fundamentally undervalued relative to its intrinsic estimate, with medium‑to‑high risk stemming from volatility (31% 30‑day) and sector‑specific regulatory exposure.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI indicating overbought conditions
- Price approaching resistance near $152
- Neutral trend direction with modest MACD histogram
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value far above current price
- Forward earnings growth and improved profitability
- Increasing trading volume supporting liquidity
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic fintech expansion and diversified revenue streams
- Stable credit rating and strong cash position
- Potential for sustained earnings growth despite current low margins
Key Metrics & Analysis
Financial Health
Revenue Growth-14.10%
Profit Margin0.18%
P/E Ratio7582.0
ROE0.22%
ROA0.03%
Debt/Equity155.89
P/B Ratio6.7
Op. Cash Flow$3.1B
Industry P/E16.6
Technical Analysis
TrendNeutral
RSI74.7
Support$127.30
Resistance$152.51
MA 20$139.34
MA 50$128.75
MA 200$147.42
MACDBullish
VolumeIncreasing
Fear & Greed Index78.8
Valuation
Fair Value$488.83
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.16
Volatility31.03%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.